PDF(Pubmed)
Abstract：
The Knight-Alzheimer Disease Research Center (Knight-ADRC) at Washington University in St. Louis has pioneered and led worldwide seminal studies that have expanded our clinical, social, pathological, and molecular understanding of Alzheimer Disease. Over more than 40 years, research volunteers have been recruited to participate in cognitive, neuropsychologic, imaging, fluid biomarkers, genomic and multi-omic studies. Tissue and longitudinal data collected to foster, facilitate, and support research on dementia and aging. The Genetics and high throughput -omics core (GHTO) have collected of more than 26,000 biological samples from 6,625 Knight-ADRC participants. Samples available include longitudinal DNA, RNA, non-fasted plasma, cerebrospinal fluid pellets, and peripheral blood mononuclear cells. The GHTO has performed deep molecular profiling (genomic, transcriptomic, epigenomic, proteomic, and metabolomic) from large number of brain (n = 2,117), CSF (n = 2,012) and blood/plasma (n = 8,265) samples with the goal of identifying novel risk and protective variants, identify novel molecular biomarkers and causal and druggable targets. Overall, the resources available at GHTO support the increase of our understanding of Alzheimer Disease.
摘要：
圣路易斯华盛顿大学的奈特-阿尔茨海默病研究中心（Knight-ADRC）开创并领导了全球开创性研究，扩大了我们的临床范围，社会,病态,和对阿尔茨海默病的分子理解。40多年来,研究志愿者被招募参与认知，神经心理学,成像,流体生物标志物，基因组和多维研究。收集的组织和纵向数据，方便,并支持痴呆症和衰老的研究。遗传学和高通量组学核心（GHTO）已从6,625名Knight-ADRC参与者中收集了26,000多个生物样本。可用的样本包括纵向DNA，RNA,非禁食血浆，脑脊液颗粒，和外周血单核细胞。GHTO进行了深度分子谱分析(基因组，转录组，表观基因组,蛋白质组学，和代谢组学)来自大量的大脑(n=2,117)，CSF（n=2,012）和血液/血浆（n=8,265）样品，目的是识别新的风险和保护性变体，识别新的分子生物标志物和因果和药物靶标。总的来说,GHTO提供的资源支持了我们对阿尔茨海默病的了解。
